PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)

被引：0
|
作者：
Saba, N. [1 ]
Youssoufian, H. [2 ]
Cohen, E. [3 ]
Singh, J. [4 ]
Makris, L. [5 ]
Perdomini, M. [6 ]
MacIntyre, S.
Denker, A. [7 ]
机构：
[1] Emory Univ, Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA
[2] Youssoufian Hagop, Med, Boston, MA USA
[3] UC San Diego Hlth, Med Dept, Moores Canc Ctr, La Jolla, CA USA
[4] AMR Kansas City Oncol, Med Dept, Kansas City, MO USA
[5] Stathmi, Stat, New Hope, PA USA
[6] Flamingo Therapeut, Clin Dev, Illkirch Graffenstaden, France
[7] Flamingo Therapeut, Clin Dev, Philadelphia, PA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
943TiP
引用
收藏
页码：S592 / S592
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
    Yeh, Justin
    Guddati, Achuta Kumar
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (06): : 1821 - 1826
  • [42] Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
    Seiwert, Tanguy Y.
    Burtness, Barbara
    Mehra, Ranee
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Heath, Karl
    McClanahan, Terrill
    Lunceford, Jared
    Gause, Christine
    Cheng, Jonathan D.
    Chow, Laura Q.
    LANCET ONCOLOGY, 2016, 17 (07): : 956 - 965
  • [43] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
    Gui, L.
    Chen, X.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1609 - S1610
  • [44] A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
    Ho, A. L.
    Adkins, D. R.
    Hanna, G. J.
    Bruce, J.
    Ahn, M. J.
    Docampo, L. Iglesias
    Kang, H.
    Wong, D. J.
    Psyrri, A.
    Gillison, M.
    Brana, I.
    Liu, Y. C.
    Hsieh, C. Y.
    Hong, M. H.
    Zhang, Z.
    Balsara, B.
    Saunders, A.
    Hernandez, A. Gasco
    Dale, S.
    Haddad, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1287
  • [45] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study
    Fuereder, T.
    Minichsdorfer, C.
    Mittlboeck, M.
    Wagner, C.
    Oberndorfer, F.
    Mullauer, L.
    Aretin, M-B.
    Czerny, C.
    Schwarz-Nemec, U.
    ANNALS OF ONCOLOGY, 2020, 31 : S665 - S665
  • [47] Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study
    Fuereder, Thorsten
    Minichsdorfer, Christoph
    Mittlboeck, Martina
    Wagner, Christina
    Heller, Gerwin
    Putz, Eva M.
    Oberndorfer, Felicitas
    Mullauer, Leonhard
    Aretin, Marie-Bernadette
    Czerny, Christian
    Schwarz-Nemec, Ursula
    ORAL ONCOLOGY, 2022, 124
  • [48] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [49] KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    Soulieres, D.
    Tahara, M.
    De Castro, G., Jr.
    Psyrri, A.
    Rotllan, N. Baste
    Neupane, P. C.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Roy, A.
    Cheng, J.
    Jin, F.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)
    Chong, W. Q.
    Low, J. L.
    Sooi, K.
    Soo, R. A.
    Le, C.
    Teo, H. L.
    Samol, J.
    Goh, G.
    Kong, L. R.
    DasGupta, R.
    Chia, S.
    Wong, R.
    Gopinathan, A.
    Tay, J. K.
    Eu, D.
    Tsang, R.
    Loh, K-S.
    Tai, B. C.
    Lim, Y. C.
    Goh, B-C.
    ANNALS OF ONCOLOGY, 2024, 35 : S614 - S614
12345